{"success":true,"data":{"pressRelease":{"id":"180974","rtpr_id":"nGNX96DPkF-20261027","ticker":"LEGN","exchange":"NASDAQ","all_tickers":["LEGN"],"title":"Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results","author":"Globe Newswire","published_at":"2026-10-27T12:00:00.881Z","article_body":"BRIDGEWATER N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation\n(NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a\nconference call for investors at 8:00 a.m. ET on Tuesday, November 10, 2026,\nto review third quarter 2026 financial results.\n\nDuring the conference call and accompanying webcast, senior management will\nprovide an overview of quarterly financial performance.\n\nInvestors and other interested parties may access the live audio webcast via\nthis weblink\n(https://www.globenewswire.com/Tracker?data=APxZ7MbQr52VhugttrBviM-aICfRfLKbR2VQIQt2Qr1eONPaL-mj7LaYWCZiwPlseshb4stt_9rKT9qWyJcAkWFBJOLJyEvxZ9y1hsCsnWE=).\n\nA replay of the webcast, along with the earnings press release, will be\navailable in the Investor Relations\n(https://www.globenewswire.com/Tracker?data=0pL4UvaKSH5nu7APmYzBxGlNI80kWsSJvP2F63WcF_JpmSlzvrogLRUROV8sEYQX6SJwMIH46lzdSwd9HANXGAHM1zCSGGPjPvssXqIErXQ=)\nsection of the Legend Biotech website under Events and Presentations\n(https://www.globenewswire.com/Tracker?data=yFggh3uRcBxCDaOaTR1hL8kAQS0cwM3cqc841nIb5o5cFRshvrKTDWMfYPwoQw2GiXFxwGOuq_DklrsCjb9NTVf_mgAbWSDpbDGseQUMHaG6lxHaS6BtBXg7c-69q-PCsQ521AyIGwU5yqCn24Nk4w==)\napproximately two hours after the conclusion of the call.\n\nABOUT LEGEND BIOTECH\n\nWith over 3,000 employees, Legend Biotech is the largest standalone cell\ntherapy company and a pioneer in treatments that change cancer care forever.\nLegend Biotech is at the forefront of the CAR-T cell therapy revolution with\nCARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma,\nwhich it develops and markets with collaborator Johnson & Johnson. Centered in\nthe United States, Legend Biotech is building an end-to-end cell therapy\ncompany by expanding its leadership to maximize CARVYKTI’s patient access\nand therapeutic potential. From this platform, Legend Biotech plans to drive\nfuture innovation across its pipeline of cutting-edge cell therapy modalities.\n\nLearn more at https://legendbiotech.com and follow us on X\n(https://www.globenewswire.com/Tracker?data=TZ8HX8QAIP7fSSnj7nilGpPtY0hVtdqlI-5KRy4HU1ZBh7OVpPDx_r9fs-38KSYbyRLA4XBTlsLG8-5p13UNb-_zg_RVhaBZS_JOTSqLhG1_BYCBRq_38wP3xM6H-PJW20SlAAxvNTkvhWPWYYVpiONp_j47rIzq6mQG2T19-vfyVz79ejOVVfqKmdwPb3t_i1DjFDsQ5SV5yeN6sUx3mg==),\nInstagram\n(https://www.globenewswire.com/Tracker?data=7itRflijevNI9uJUcfO7amPpa1DXRnDkwn5cJS1XqVx3BNPqoDqEy1KW_Sc6G0BjApidn4XBxMdhpRu-dIBC9wD7tRLRtYpyLgfofaFLfYDsAopJH7Eu5nAUM2jVABFbmgRcU_GvvXnU71j_LJ-PIPmi5tolGr175GPPdVRE3W-zc1EQuuaFzCb-l9EQ2TnCk-AHKXMziyvLMZSpo2E0Ea1mB0y53Fs4xCOP68sipN-qY3SbELNmlzKa3_VdldznF8TaXAUsLiUSjffmIodClLHYc8XaoktXA6Sw7Jk5SpmKEYKDNheeB1GYdQ1hgC30),\nand LinkedIn\n(https://www.globenewswire.com/Tracker?data=6_f7tebGmTga_a4Jwe8nr49aqau8BGv6SAx4xi7T2d8ccVhLCltUnHg3CNLwX-GCCKL-JM3OMA2LVMNV1zzcTImawo6XJQmz85mLygJiAO9ICx7fF1k79uQ_0fLFakNVlpUqJD_zOIdex6D5L1PaejVypXTDz1kdxZOMTcW9Vd80cCJV1W8m2eTCBwKnjJVqmUw4NdvcQi_bV5MVEsrWZCL-p6N186v70AXvQX8tphRJqgLcXuhbYmBUIl_F6t-G7RlIoA8rIuEs5Plre31V_nKK9lJiuBf4rsy1Rl6NiHUxc42H8knIEM6pEKwdrDV5).\n\nINVESTOR CONTACT:\nCaroline Paul\nTel: (973) 650-5832\nCaroline.Paul@legendbiotech.com\n\nPRESS CONTACT:\nKim Fox\nTel: (848) 388-8445\nmedia@legendbiotech.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/d3a680c2-cab6-4eb2-9ed0-7be055f9e180)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX96DPkF-20261027","title":"Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results","author":"Globe Newswire","ticker":"LEGN","created":"2026-10-27T12:00:00.881Z","tickers":["LEGN"],"exchange":"NASDAQ","article_body":"BRIDGEWATER N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation\n(NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a\nconference call for investors at 8:00 a.m. ET on Tuesday, November 10, 2026,\nto review third quarter 2026 financial results.\n\nDuring the conference call and accompanying webcast, senior management will\nprovide an overview of quarterly financial performance.\n\nInvestors and other interested parties may access the live audio webcast via\nthis weblink\n(https://www.globenewswire.com/Tracker?data=APxZ7MbQr52VhugttrBviM-aICfRfLKbR2VQIQt2Qr1eONPaL-mj7LaYWCZiwPlseshb4stt_9rKT9qWyJcAkWFBJOLJyEvxZ9y1hsCsnWE=).\n\nA replay of the webcast, along with the earnings press release, will be\navailable in the Investor Relations\n(https://www.globenewswire.com/Tracker?data=0pL4UvaKSH5nu7APmYzBxGlNI80kWsSJvP2F63WcF_JpmSlzvrogLRUROV8sEYQX6SJwMIH46lzdSwd9HANXGAHM1zCSGGPjPvssXqIErXQ=)\nsection of the Legend Biotech website under Events and Presentations\n(https://www.globenewswire.com/Tracker?data=yFggh3uRcBxCDaOaTR1hL8kAQS0cwM3cqc841nIb5o5cFRshvrKTDWMfYPwoQw2GiXFxwGOuq_DklrsCjb9NTVf_mgAbWSDpbDGseQUMHaG6lxHaS6BtBXg7c-69q-PCsQ521AyIGwU5yqCn24Nk4w==)\napproximately two hours after the conclusion of the call.\n\nABOUT LEGEND BIOTECH\n\nWith over 3,000 employees, Legend Biotech is the largest standalone cell\ntherapy company and a pioneer in treatments that change cancer care forever.\nLegend Biotech is at the forefront of the CAR-T cell therapy revolution with\nCARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma,\nwhich it develops and markets with collaborator Johnson & Johnson. Centered in\nthe United States, Legend Biotech is building an end-to-end cell therapy\ncompany by expanding its leadership to maximize CARVYKTI’s patient access\nand therapeutic potential. From this platform, Legend Biotech plans to drive\nfuture innovation across its pipeline of cutting-edge cell therapy modalities.\n\nLearn more at https://legendbiotech.com and follow us on X\n(https://www.globenewswire.com/Tracker?data=TZ8HX8QAIP7fSSnj7nilGpPtY0hVtdqlI-5KRy4HU1ZBh7OVpPDx_r9fs-38KSYbyRLA4XBTlsLG8-5p13UNb-_zg_RVhaBZS_JOTSqLhG1_BYCBRq_38wP3xM6H-PJW20SlAAxvNTkvhWPWYYVpiONp_j47rIzq6mQG2T19-vfyVz79ejOVVfqKmdwPb3t_i1DjFDsQ5SV5yeN6sUx3mg==),\nInstagram\n(https://www.globenewswire.com/Tracker?data=7itRflijevNI9uJUcfO7amPpa1DXRnDkwn5cJS1XqVx3BNPqoDqEy1KW_Sc6G0BjApidn4XBxMdhpRu-dIBC9wD7tRLRtYpyLgfofaFLfYDsAopJH7Eu5nAUM2jVABFbmgRcU_GvvXnU71j_LJ-PIPmi5tolGr175GPPdVRE3W-zc1EQuuaFzCb-l9EQ2TnCk-AHKXMziyvLMZSpo2E0Ea1mB0y53Fs4xCOP68sipN-qY3SbELNmlzKa3_VdldznF8TaXAUsLiUSjffmIodClLHYc8XaoktXA6Sw7Jk5SpmKEYKDNheeB1GYdQ1hgC30),\nand LinkedIn\n(https://www.globenewswire.com/Tracker?data=6_f7tebGmTga_a4Jwe8nr49aqau8BGv6SAx4xi7T2d8ccVhLCltUnHg3CNLwX-GCCKL-JM3OMA2LVMNV1zzcTImawo6XJQmz85mLygJiAO9ICx7fF1k79uQ_0fLFakNVlpUqJD_zOIdex6D5L1PaejVypXTDz1kdxZOMTcW9Vd80cCJV1W8m2eTCBwKnjJVqmUw4NdvcQi_bV5MVEsrWZCL-p6N186v70AXvQX8tphRJqgLcXuhbYmBUIl_F6t-G7RlIoA8rIuEs5Plre31V_nKK9lJiuBf4rsy1Rl6NiHUxc42H8knIEM6pEKwdrDV5).\n\nINVESTOR CONTACT:\nCaroline Paul\nTel: (973) 650-5832\nCaroline.Paul@legendbiotech.com\n\nPRESS CONTACT:\nKim Fox\nTel: (848) 388-8445\nmedia@legendbiotech.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/d3a680c2-cab6-4eb2-9ed0-7be055f9e180)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-27T12:00:01.010834794Z","server_sent_at_ms":1793102401010},"received_at":"2026-10-27T12:00:01.076Z","source_url":null},"analysis":{"id":"168793","press_release_id":"180974","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Legend Biotech will host a conference call at 8:00 a.m. ET on Tuesday, November 10, 2026, to review third quarter 2026 financial results.\n\nThe call includes a webcast with senior management covering quarterly financial performance, and a replay plus earnings release will post to the company's investor relations site about two hours after the call.\n\nThis is a scheduling notice only; no results are included.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Earnings date notice -- calendar the Nov 10 Q3 call for LEGN; no action needed now."},"keyFigures":{"customDimensions":{"callDate":"November 10, 2026, 8:00 a.m. ET"}},"namedEntities":{"people":[{"name":"Caroline Paul","role":"Investor contact"},{"name":"Kim Fox","role":"Press contact"}],"products":["CARVYKTI"],"companies":[{"name":"Legend Biotech Corporation","ticker":"LEGN","relationship":"filer"},{"name":"Johnson & Johnson","relationship":"collaborator"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Boilerplate scheduling notice announcing when Q3 2026 results will be reviewed. No financial figures or guidance are disclosed."},"tickerRelevance":{"others":[{"ticker":"JNJ","relevance":"CARVYKTI co-development and co-marketing collaborator"}],"primary":"LEGN"},"globalImportance":5,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap biotech","eventGravity":"earnings-date-notice","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Legend Biotech will host a conference call at 8:00 a.m. ET on Tuesday, November 10, 2026, to review third quarter 2026 financial results.\n\nThe call includes a webcast with senior management covering quarterly financial performance, and a replay plus earnings release will post to the company's investor relations site about two hours after the call.\n\nThis is a scheduling notice only; no results are included.","key_figures":{"customDimensions":{"callDate":"November 10, 2026, 8:00 a.m. ET"}},"named_entities":{"people":[{"name":"Caroline Paul","role":"Investor contact"},{"name":"Kim Fox","role":"Press contact"}],"products":["CARVYKTI"],"companies":[{"name":"Legend Biotech Corporation","ticker":"LEGN","relationship":"filer"},{"name":"Johnson & Johnson","relationship":"collaborator"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-27T12:00:14.026Z","global_importance":5,"audience_relevance":20,"importance_components":{"tickerTier":"mid-cap biotech","eventGravity":"earnings-date-notice","issuerAuthored":true}},"durationMs":4436,"modelName":"glm-5.3-flashx"}}